CDC Finds Vaccination Coverage Varies for Adults With Diabetes

Share this content:
CDC Finds Vaccination Coverage Varies for Adults With Diabetes
CDC Finds Vaccination Coverage Varies for Adults With Diabetes

MONDAY, Dec. 12, 2016 (HealthDay News) -- Among adults with diagnosed diabetes, vaccination coverage varies, with influenza vaccination more prevalent than pneumococcal or hepatitis B vaccination, according to a December data brief published by the U.S. Centers for Disease Control and Prevention's National Center for Health Statistics (NCHS).

Using data from the National Health Interview Survey, Maria A. Villarroel, Ph.D., and Anjel Vahratia, Ph.D., from the NCHS in Hyattsville, Md., describe the receipt of select vaccinations among adults with diagnosed diabetes.

The researchers found that 61.6 percent of adults aged 18 years and older with diagnosed diabetes had an influenza vaccine in the past year. At some time in the past, 52.6 percent had a pneumococcal vaccine and 17.1 percent had the three-dose vaccination schedule for hepatitis B. Overall, 27.2 percent of adults aged 60 years and older with diagnosed diabetes had ever had a shingles vaccine. Influenza, pneumococcal, and shingles vaccination coverage was lowest among poor adults, increased with age, and varied based on race and ethnicity. Poor adults had the lowest hepatitis B vaccination coverage, and it decreased with age.

"Among adults aged 18 and over with diagnosed diabetes, influenza vaccination (61.6 percent) was more prevalent than pneumococcal (52.6 percent) and hepatitis B (17.1 percent) vaccination," the authors write. "Fewer than three in 10 (27.2 percent) adults aged 60 and over with diagnosed diabetes had been vaccinated for shingles."

Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

FDA Approves Kinase Inhibitor for Treatment of AML

FDA Approves Kinase Inhibitor for Treatment of AML

Midostaurin, in combination with chemotherapy, treats acute myeloid leukemia in adults

Enzyme Replacement Drug OK'd for Form of Batten Disease

Enzyme Replacement Drug OK'd for Form of Batten ...

Brineura will be used to treat children with late infantile neuronal ceroid lipofuscinosis type 2 Batten

is free, fast, and customized just for you!

Already a member?

Sign In Now »